文献速递肝病消化道肿瘤与早癌

单羧酸转运蛋白4抑制通过增强T细胞浸润和免疫攻击增强肝细胞癌免疫治疗

Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
PubMed 文献 · Hepatology · 2022-02-07

研究显示MCT4在肝细胞癌中过表达且与不良预后相关。遗传或药物抑制MCT4可增强CD8+ T细胞浸润和细胞毒性,抑制肿瘤生长,并改善抗PD-1免疫治疗疗效、延长小鼠生存。MCT4高表达见于接受特瑞普利单抗新辅助治疗无应答患者的肿瘤组织。

要点

  • MCT4在肝细胞癌中过表达,与患者不良预后相关。
  • 抑制MCT4可增强CD8+ T细胞浸润和细胞毒性,抑制免疫健全小鼠肿瘤生长。
  • MCT4抑制联合抗PD-1免疫治疗改善疗效并延长小鼠生存。

核心结论

  • MCT4介导的乳酸外排具有肿瘤内在功能,可生成免疫抑制性肝细胞癌环境。
  • 靶向MCT4在定制肝细胞癌免疫治疗策略中具有概念验证意义。

研究设计与样本

  • 研究在肝细胞癌中检测MCT4表达并分析其与预后的关联。
  • 使用遗传或药物抑制MCT4(VB124,一种高效MCT4抑制剂)在免疫健全小鼠模型中观察肿瘤生长。
  • 分析MCT4抑制对CD8+ T细胞浸润和细胞毒性的影响及与抗PD-1免疫治疗联合的效果。
  • 检测接受特瑞普利单抗新辅助治疗的肝细胞癌无应答患者肿瘤组织中MCT4表达。

主要发现

  • MCT4在肝细胞癌中过表达,与患者不良预后相关。
  • 遗传或药物抑制MCT4抑制免疫健全小鼠模型中肝细胞癌肿瘤生长。
  • MCT4抑制增强CD8+ T细胞浸润和细胞毒性。
  • MCT4抑制缓解肿瘤微环境酸化并升高活性氧/NF-κB信号通路诱导的CXCL9/CXCL10分泌。
  • MCT4抑制联合抗PD-1免疫治疗改善肝细胞癌治疗获益并延长小鼠生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Monocarboxylate transporter (MCT) 4 is a high-affinity lactate transporter that is primarily involved in the maintenance of intracellular pH homeostasis and highly expressed in different tumors. However, the role of MCT4 in modulating immune responses against HCC remains unknown. APPROACH AND RESULTS: In this study, we demonstrated that MCT4 was overexpressed in HCC, which was associated with poor prognosis in patients. Genetic or pharmacological inhibition of MCT4 using VB124 (a highly potent MCT4 inhibitor) suppressed HCC tumor growth in immunocompetent mice model by enhancing CD8 + T cell infiltration and cytotoxicity. Such improved immunotherapy response by MCT4 targeting was due to combined consequences characterized by the alleviated acidification of tumor microenvironment and elevated the chemokine (C-X-C motif) ligand (CXCL) 9/CXCL10 secretion induced by reactive oxygen species/NF-κB signaling pathway. Combining MCT4 inhibition improved the therapeutic benefit of anti-programmed cell death 1 immunotherapy in HCC and prolonged mice survival. Moreover, higher MCT4 expression was observed in tumor tissues from nonresponder patients with HCC receiving neoadjuvant therapy with toripalimab. CONCLUSIONS: Our results revealed that lactate exportation by MCT4 has a tumor-intrinsic function in generating an immunosuppressive HCC environment and demonstrated the proof of the concept of targeting MCT4 in tailoring HCC immunotherapeutic approaches.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Fang Y, Liu W, Tang Z, et al. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology. 2022. PMID: 35043976. doi:10.1002/hep.32348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。